Summit Therapeutics Inc header image

Summit Therapeutics Inc

SMMT

Equity

ISIN null / Valor 56903013

NASDAQ (2026-11-03)
USD 15.80+6.76%

Summit Therapeutics Inc
UMushroom community rating:

star star star star star
4.91 3 votes No rating yet
NegativeNeutralPositive

About company

Summit Therapeutics Inc. is a biopharmaceutical company specializing in oncology, dedicated to the discovery, development, and commercialization of innovative therapies aimed at addressing serious unmet medical needs. The company's primary focus is on improving the quality and potential duration of life for patients with challenging cancer diagnoses. Summit's lead candidate, ivonescimab (SMT112 in the U.S., Canada, Europe, and Japan; AK112 in China and Australia), is a novel bispecific antibody that combines immunotherapy and anti-angiogenesis effects. Currently, ivonescimab is undergoing two Phase III clinical trials in Summit's licensed territories and multiple Phase III trials in China, led by its discoverer, Akeso, Inc. Initially targeting non-small cell lung cancer (NSCLC), Summit plans to explore ivonescimab's potential in other solid tumors, leveraging promising data from ongoing studies.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-13.3%1Y
686%3Y
185%5Y

Performance

72.1%1Y
128%3Y
135%5Y

Volatility

Market cap

12604 M

Market cap (USD)

Daily traded volume (Shares)

6,045,173

Daily traded volume (Shares)

1 day high/low

18.15 / 17.57

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.91

3 votes
Performance:
starstarstarstarstar
4.45
Innovation:
starstarstarstarstar
4.45
Society:
starstarstarstarstar
4.36
Nature:
starstarstarstarstar
4.36
Zi Xing Gan
UK, 23 Oct 2026
star star star star star
Exciting approval upcoming
William Tanex
UK, 21 Oct 2026
star star star star star
worth the risk. waiting for FDA approval
D Y
Switzerland, 28 Mar 2025
star star star star star
Not sure

EQUITIES OF THE SAME SECTOR

FibroGen Inc
FibroGen Inc FibroGen Inc Valor: 25953994
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.36%USD 4.31
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Inc Valor: 24112479
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
9.08%USD 14.29
Evotec SE
Evotec SE Evotec SE Valor: 505433
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.85%EUR 2.86
Evolent Health Inc
Evolent Health Inc Evolent Health Inc Valor: 28153126
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.37%USD 4.30
ALX Oncology Holdings Inc
ALX Oncology Holdings Inc ALX Oncology Holdings Inc Valor: 55754366
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.84%USD 1.29
Hims & Hers Health Inc
Hims & Hers Health Inc Hims & Hers Health Inc Valor: 59397181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%USD 25.70
Pacira BioSciences Inc
Pacira BioSciences Inc Pacira BioSciences Inc Valor: 12338490
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.03%USD 36.39
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc Ironwood Pharmaceuticals Inc Valor: 10773079
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.16%USD 3.50
Addus HomeCare Corp
Addus HomeCare Corp Addus HomeCare Corp Valor: 10385048
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.64%USD 126.55
Arvinas Inc
Arvinas Inc Arvinas Inc Valor: 43526042
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.72%USD 7.09